<code id='39FCDBC9A5'></code><style id='39FCDBC9A5'></style>
      • <acronym id='39FCDBC9A5'></acronym>
      <center id='39FCDBC9A5'><center id='39FCDBC9A5'><tfoot id='39FCDBC9A5'></tfoot></center><abbr id='39FCDBC9A5'><dir id='39FCDBC9A5'><tfoot id='39FCDBC9A5'></tfoot><noframes id='39FCDBC9A5'>
      • <optgroup id='39FCDBC9A5'><strike id='39FCDBC9A5'><sup id='39FCDBC9A5'></sup></strike><code id='39FCDBC9A5'></code></optgroup>
        5. <b id='39FCDBC9A5'><label id='39FCDBC9A5'><select id='39FCDBC9A5'><dt id='39FCDBC9A5'><span id='39FCDBC9A5'></span></dt></select></label></b><u id='39FCDBC9A5'></u>
          <i id='39FCDBC9A5'><strike id='39FCDBC9A5'><tt id='39FCDBC9A5'><pre id='39FCDBC9A5'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / knowledge / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-09-30 21:55:33 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：hotspot   
                                        
                                      
                                      Page View：5
                                  
                                    
          
                                   
          Adobe
          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.
          The deal includes up to another $400 million in payments if certain milestones are met.
          advertisement
          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          After decades in use, heart stents finally beat placebo
                                
                            
          Next article：  
                                      
                                          How to save PrEP access — and even expand it
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles